The estimated Net Worth of David E I Pyott is at least $9.01 Million dollars as of 24 June 2024. Mr. Pyott owns over 32,450 units of Alnylam Pharmaceuticals Inc stock worth over $8,534,599 and over the last 21 years he sold ALNY stock worth over $0. In addition, he makes $470,707 as Independent Director at Alnylam Pharmaceuticals Inc.
David has made over 28 trades of the Alnylam Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 32,450 units of ALNY stock worth $2,620,662 on 24 June 2024.
The largest trade he's ever made was exercising 32,450 units of Alnylam Pharmaceuticals Inc stock on 24 June 2024 worth over $2,620,662. On average, David trades about 1,283 units every 38 days since 2003. As of 24 June 2024 he still owns at least 32,586 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Mr. Pyott stock trades at the bottom of the page.
David E.I. Pyott is an Independent Director of the Alnylam Pharmaceuticals, Inc. Mr. Pyott served as the Chief Executive Officer of Allergan, Inc., a global specialty pharmaceutical and medical device company, from January 1998 to March 2015 and as the Chair of Allergan’s board of directors from March 2001 until March 2015. Prior to Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. Mr. Pyott also serves as the lead independent director at Avery Dennison Corporation, a director of BioMarin Pharmaceutical Inc. and a member of the Supervisory Board of Royal Philips in the Netherlands. Mr. Pyott formerly served as a director of Edwards Lifesciences Corporation.
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of David Pyott at Alnylam Pharmaceuticals Inc is $470,707. There are 17 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
David Pyott is 67, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2015. There are 2 older and 17 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
David's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: